Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.60 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.60 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.60 |
| ▸ | BDKRB1 | P46663 | 14/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | BDKRB2 | P30411 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644970 | 0.95 | CACNA2D1 (0.56) | CACNA2D1CACNA1BCACNB1CACNA1CBDKRB1 | |
| SCHEMBL645024 | 0.93 | CACNA2D1 (0.51) | CACNA2D1CACNA1BCACNB1CACNA1CBDKRB1 | |
| SCHEMBL643832 | 0.84 | BDKRB1 (0.49) | BDKRB1BDKRB2 | |
| SCHEMBL642813 | 0.83 | BDKRB1 (0.49) | BDKRB1BDKRB2 | |
| SCHEMBL3404305 | 0.81 | RAB9A (0.50) | BDKRB1RAB9ABDKRB2ALDH1A1MAPT | |
| SCHEMBL2797186 | 0.80 | CACNA2D1 (0.92) | CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL3405377 | 0.76 | RAB9A (0.45) | BDKRB1RAB9ABDKRB2ALDH1A1KMT2A | |
| SCHEMBL3410238 | 0.76 | BDKRB1 (0.47) | BDKRB1RAB9ABDKRB2ALDH1A1KMT2A | |
| SCHEMBL4374587 | 0.75 | BDKRB1 (0.47) | BDKRB1RAB9ABDKRB2ALDH1A1KMT2A | |
| SCHEMBL3409680 | 0.75 | BDKRB1 (0.48) | BDKRB1RAB9ABDKRB2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150530-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-10-26 | — | — | EP | claimed |
| EP-2150530-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-02-10 | — | — | EP | claimed |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-18 | — | — | US | claimed |
| WO-2008131947-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | claimed |
| US-8119633-B2 | N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| EP-2150530-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-10-26 | — | — | EP | disclosed |
| EP-2150530-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| WO-2008131947-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312231-A1 | Substituted Sulfonamide Compounds | SULT2A1, SULT1A1, SCN1A | CACNA2D1 1158/4885CACNA1B 279/4885CACNB1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.